Results 151 to 160 of about 319,649 (342)

Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial

open access: yesStem Cell Research & Therapy
Background Kidney function declines with age, largely due to chronic low-grade inflammation. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory effects in certain immune-mediated kidney diseases, but their role in preserving renal function ...
Juan D. Martinez-Lemus   +8 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Association between eGFR and neurological outcomes among patients with out‐of‐hospital cardiac arrest: A nationwide prospective study in Japan

open access: yesAcute Medicine & Surgery
Aim We aimed to investigate the association between estimated glomerular filtration rate and prognosis in out‐of‐hospital cardiac arrest patients and explore the heterogeneity of the association.
Kenji Kandori   +8 more
doaj   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang   +5 more
wiley   +1 more source

Supplementary Material for: Association of Albuminuria and Estimated Glomerular Filtration Rate with Functional Performance Measures in Older Adults with Chronic Kidney Disease

open access: green, 2017
Dawn F. Wolfgram   +9 more
openalex   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

PS3-34: Does Reporting of Estimated Glomerular Filtration Rates Affect Clinician Behavior? [PDF]

open access: diamond, 2013
Micah L. Thorp   +7 more
openalex   +1 more source

Home - About - Disclaimer - Privacy